PCRX Pacira BioSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1396814 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.7%
TTM net income YoY76.0%
TTM EPS YoY97.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR75.5%
Margins
Gross margin78.7%
Operating margin4.8%
Net margin5.1%
FCF margin22.7%
EBITDA margin12.4%
Returns
ROE5.2%
ROA3.0%
ROIC (approx.)4.2%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets40.8%
Debt / equity0.41x
Current ratio4.68x
Interest coverage2.54x
Cash quality & payout
Operating cash flow / net income4.69x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $726.41M | $700.97M |
| Cost of revenue | $149.75M | $170.43M |
| Gross profit | $576.66M | $530.54M |
| R&D expense | $117.31M | $81.58M |
| SG&A expense | $368.76M | $294.10M |
| Operating income | $19.19M | -$73.37M |
| Interest expense | $17.45M | $16.57M |
| Pretax income | $16.87M | -$63.11M |
| Income tax | $9.84M | $36.45M |
| Net income | $7.03M | -$99.56M |
| EBITDA | $110.21M | $5.41M |
| EPS (basic) | 0.16 | -2.15 |
| EPS (diluted) | 0.16 | -2.15 |
| Weighted avg. shares (diluted) | 45.04M | 46.24M |
| Balance sheet | ||
| Cash & equivalents | $158.54M | $276.77M |
| Short-term investments | $79.88M | $207.84M |
| Receivables | $124.07M | $113.30M |
| Inventory | $152.86M | $125.28M |
| Current assets | $547.97M | $745.13M |
| PP&E, net | $140.69M | $167.17M |
| Goodwill | $20.21M | $0 |
| Intangibles | $368.10M | $425.97M |
| Total assets | $1.26B | $1.55B |
| Current liabilities | $120.59M | $309.92M |
| Short-term debt | $0 | $201.78M |
| Long-term debt | $372.19M | $383.55M |
| Total debt | $372.19M | $585.32M |
| Total liabilities | $571.81M | $775.17M |
| Shareholders' equity | $693.11M | $778.35M |
| Net debt | $213.64M | $308.55M |
| Shares outstanding | 41.12M | 46.24M |
| Cash flow statement | ||
| Operating cash flow | $151.99M | $189.39M |
| Capital expenditure | $15.33M | $10.64M |
| Free cash flow | $136.66M | $178.75M |
| Investing cash flow | $99.48M | -$83.28M |
| Financing cash flow | -$369.63M | $17.36M |
| Depreciation & amortization | $91.02M | $78.78M |
| Stock-based compensation | $57.50M | $51.17M |
| Share buybacks | $148.33M | $25.00M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.